This seasoned chieftain has been a blizzard of activity in recent months: selling off a portion of Abbott’s generics business, acquiring Chile’s CFR Pharmaceuticals, and expanding into new technology areas within vascular-device and eye-care fields. While revenues and profits were essentially flat in 2014, as of presstime, the drug maker’s stock was on the rise.